SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
REDWOOD CITY, Calif., May 25, 2017 -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced a schedule of sessions highlighting the company’s Lumivascular™ technology at the upcoming New Cardiovascular Horizons conference taking place next week in New Orleans from Tuesday, May 30, through Friday, June 2, 2017.
Avinger Lumivascular technology highlights include the following presentations by Patrick Muck, M.D., vascular surgeon at Good Samaritan Hospital in Cincinnati, Ohio:
Tuesday, May 30
- “Optical Coherence Tomography (OCT): Role in Modern Cath Lab,” Crescent City Ballroom, 12:50 – 1:00pm CT
Wednesday, May 31
- “First Look: 24-Month Outcomes from the Pivotal VISION Trial for OCT-Guided Directional Atherectomy,” Waldorf Astoria Ballroom, 11:20 – 11:28pm CT
Thursday, June 1
- “Minimally Invasive Endarterectomy: Using Optical Coherence Tomography (OCT) to Guide Precision Debulking,” Crescent City Ballroom, 8:24 – 8:32pm CT
Materials related to certain sessions listed above will be posted to Avinger’s website following their presentation at the conference.
About Avinger, Inc.
Avinger, Inc. is dedicated to radically changing the way peripheral artery disease (PAD) is treated. The company’s Lumivascular platform, the first-ever image-guided catheter-based systems to diagnose and treat patients with PAD, includes the Lightbox imaging console, the Ocelot family of catheters for chronic total occlusions, and the Pantheris® atherectomy device. Avinger is based in Redwood City, Calif. For more information, please visit www.avinger.com.
Public Relations Contact: Phil Preuss Avinger, Inc. (650) 241-7900 [email protected] Investor Contact: Matt Ferguson Avinger, Inc. (650) 241-7917 [email protected]
